DR. SABINE MUELLER, MD, PHD
Medical Practice at Parnassus Ave, San Francisco, CA
License number
California A96526
Category
Medical Practice
Type
Specialist
Address
Address
400 Parnassus Ave, San Francisco, CA 94143
Phone
(415) 353-2273
Personal information
See more information about SABINE MUELLER at radaris.comName
Address
Phone
456 Haight St, San Francisco, CA 94117
Organization information
See more information about SABINE MUELLER at bizstanding.comSabine Mueller MD,PHD
400 Parnassus Ave, San Francisco, CA 94122
Industry:
Neurologist, Pediatrician
Phone:
(415) 353-2525 (Phone)
Sabine P. Mueller
Professional information
Sabine P Mueller, San Francisco CA
Specialties:
Pediatrics, Neurology with Special Qualifications in Child Neurology
Work:
UCSF Medical Center / Moffitt-Long Hospitals
400 Parnassus Ave, San Francisco, CA 94143
400 Parnassus Ave, San Francisco, CA 94143
Education:
Universitaet Hamburg (2003)
Dr. Sabine Mueller, San Francisco CA - MD (Doctor of Medicine)
Specialties:
Pediatric Neurology
Address:
MCB300
400 Parnassus Ave SUITE 1ST, San Francisco 94143
(415) 353-4602 (Phone), (415) 353-4602 (Fax)
400 Parnassus Ave SUITE 1ST, San Francisco 94143
(415) 353-4602 (Phone), (415) 353-4602 (Fax)
Languages:
English
Sabine Mueller, San Francisco CA
Specialties:
Pediatric Neurologist
Address:
400 Parnassus Ave, San Francisco, CA 94143
Use Of Protein Tyrosine Phosphatase Zeta As A Biomolecular Target In The Treatment And Visualization Of Brain Tumors
US Patent:
2002014, Oct 10, 2002
Filed:
Mar 23, 2001
Appl. No.:
09/816703
Inventors:
Sabine Mueller - San Francisco CA, US
Thorsten Melcher - San Francisco CA, US
Daniel Chin - Foster City CA, US
Thorsten Melcher - San Francisco CA, US
Daniel Chin - Foster City CA, US
Assignee:
AGY THERAPEUTICS
International Classification:
A61K051/00, A61M036/14
US Classification:
424/001690
Abstract:
The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to human protein tyrosine phosphatase-zeta (PTP ) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
Use Of Protein Biomolecular Targets In The Treatment And Visualization Of Brain Tumors
US Patent:
7060275, Jun 13, 2006
Filed:
Aug 28, 2003
Appl. No.:
10/652981
Inventors:
Sabine Mueller - San Francisco CA, US
Thorsten Melcher - San Francisco CA, US
Daniel Chin - Foster City CA, US
Thorsten Melcher - San Francisco CA, US
Daniel Chin - Foster City CA, US
Assignee:
AGY Therapeutics, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61K 39/40, C07H 21/02
US Classification:
4241781, 436 231, 436 232, 436 235
Abstract:
The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTPζ) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2.
Monoclonal Antibodies Directed To Receptor Protein Tyrosine Phosphatase Zeta
US Patent:
2005026, Nov 24, 2005
Filed:
Mar 31, 2005
Appl. No.:
11/097728
Inventors:
Daniel Chin - Foster City CA, US
Erik Foehr - Novato CA, US
Sabine Mueller - San Francisco CA, US
Thorsten Melcher - San Francisco CA, US
Erik Foehr - Novato CA, US
Sabine Mueller - San Francisco CA, US
Thorsten Melcher - San Francisco CA, US
International Classification:
A61K051/00, A61K039/395
US Classification:
424001490, 424146100
Abstract:
The present invention relates to a method of inhibiting growth of tumor cells which overexpress a receptor protein tyrosine phosphatase zeta (PTPζ) by treatment of the cells with antibodies which recognize PTPζ and/or inhibit PTPζ function. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
Use Of Biomolecular Targets In The Treatment And Visualization Of Tumors
US Patent:
7368098, May 6, 2008
Filed:
Dec 23, 2002
Appl. No.:
10/328544
Inventors:
Sabine Mueller - San Francisco CA, US
Mirella Gonzalez-Zulueta - Pacifica CA, US
Erik Foehr - Novato CA, US
Daniel J. Chin - Foster City CA, US
Mirella Gonzalez-Zulueta - Pacifica CA, US
Erik Foehr - Novato CA, US
Daniel J. Chin - Foster City CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
G01N 33/574
US Classification:
424 149, 435 4, 435 723
Abstract:
The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expressed in tissues from adenocarcinoma, non-melanoma, and renal carcinoma cells. Immunotherapeutic and immunoimaging agents that specifically bind to an identified brain tumor target protein are provided. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
Use Of Biomolecular Targets In The Treatment And Visualization Of Brain Tumors
US Patent:
7014838, Mar 21, 2006
Filed:
Dec 23, 2002
Appl. No.:
10/329258
Inventors:
Sabine Mueller - San Francisco CA, US
Mirella Gonzalez-Zulueta - Pacifica CA, US
Erik Foehr - Novato CA, US
Daniel J. Chin - Foster City CA, US
Mirella Gonzalez-Zulueta - Pacifica CA, US
Erik Foehr - Novato CA, US
Daniel J. Chin - Foster City CA, US
Assignee:
AGY Therapeutics, Inc. - South San Francisco CA
International Classification:
A61K 51/00, A61M 36/14
US Classification:
424 169, 424 111, 424 149, 424 165, 424 91, 424 92
Abstract:
The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents, which specifically bind to one or more of the identified brain tumor protein targets. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.